Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Thyroid cancer in 2010

A roadmap for targeted therapies

Nature Reviews Endocrinology volume 7, pages 65–67 (2011)Cite this article

Subjects

Landmark studies published in 2010 have shed new light on the biology of thyroid cancer. From cooperation between various genetic lesions during thyroid carcinogenesis to identification of the cell type primarily affected, the results of these studies offer a solid framework for future development of targeted thyroid cancer therapies.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The growth factor signaling cascade.

References

  1. Tuttle, R. M. et al. Thyroid carcinoma. J. Natl Compr. Canc. Netw. 8, 1228–1274 (2010).

    Article  PubMed  Google Scholar 

  2. Lam, E. T. et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol. 28, 2323–2330 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wells, S. A. Jr et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28, 767–772 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Robinson, B. G., Paz-Ares, L., Krebs, A., Vasselli, J. & Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95, 2664–2671 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bible, K. C. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 11, 962–972 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ricarte-Filho, J. C. et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885–4893 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Miller, K. A. et al. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 69, 3689–3694 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Todaro, M. et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 70, 8874–8885 (2010).

    Article  CAS  PubMed  Google Scholar 

  9. Gandhi, M., Dillon, L. W., Pramanik, S., Nikiforov, Y. E. & Wang, Y. H. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 29, 2272–2280 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ameziane–El-Hassani, R. et al. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res. 70, 4123–4132 (2010).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Biologia e Patologia Cellulare e Molecolare L Califano, Universita' degli studi di Napoli, Via Pansini 5, Naples, 80131, Italy

    Francesca Carlomagno & Massimo Santoro

Authors
  1. Francesca Carlomagno
    View author publications

    Search author on:PubMed Google Scholar

  2. Massimo Santoro
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Massimo Santoro.

Ethics declarations

Competing interests

M. Santoro has received research grant support from AstraZeneca. F. Carlomagno declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carlomagno, F., Santoro, M. A roadmap for targeted therapies. Nat Rev Endocrinol 7, 65–67 (2011). https://doi.org/10.1038/nrendo.2010.232

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2010.232

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer